Beyond the Protein-Coding Sequence: Noncoding RNAs in the Pathogenesis of Type 2 Diabetes

Johanna K. DiStefano

Translational Genomics Research Institute, 445 North Fifth Street, Phoenix, AZ 85004, USA

Manuscript submitted February 24, 2015; resubmitted April 1, 2015; accepted April 2, 2015

Abstract

Diabetes mellitus results from a deficiency or failure to maintain normal glucose homeostasis. The most common form of the disease is type 2 diabetes (T2D), a progressive metabolic disorder characterized by elevated glucose levels that develops in response to either multi-organ insulin resistance or insufficient insulin secretion from pancreatic β-cells. Although the etiology of T2D is complex, many factors are known to contribute to defects of glucose homeostasis, including obesity, unhealthy lifestyle choices, genetic susceptibility, and environmental exposures. In addition to these factors, noncoding RNAs (ncRNAs) have been recently implicated in the pathogenesis of T2D, playing roles in several of the pathophysiological mechanisms underlying the disease, particularly in insulin-sensitive tissues such as pancreatic β-cells, liver, muscle, and adipose tissue. A growing number of publications demonstrate that polymorphisms in ncRNAs or their target genes may represent a new class of genetic variation contributing to the development of T2D. This review summarizes both the current state of knowledge of ncRNAs, specifically microRNAs (miRNAs), involved in the regulation of β-cell function, insulin sensitivity, and insulin action in peripheral organs. The role of genetic variation in miRNAs or miRNA binding sites in the pathogenesis of T2D is also discussed. While far less is known about the impact of long ncRNAs (lncRNAs) in the development of T2D, emerging evidence suggests that these molecules may be able to contribute to β-cell dysfunction in response to hyperglycemia. This article provides an overview of the studies conducted to date in this field, focusing on lncRNAs that are dysregulated in human pancreatic islets.

Keywords: type 2 diabetes • noncoding RNA • microRNA • miRNA-binding site • IncRNA • epigenetics • beta-cell • insulin resistance • genetic variant • SNP

1. Introduction

Diabetes mellitus, a multifactorial, heterogeneous collection of disorders, results from a deficiency or failure to maintain normal glucose homeostasis. Type 2 diabetes (T2D) develops in response to multi-organ insulin resistance and/or inadequate insulin secretion from pancreatic β-cells [1, 2]. Due to a combination of different factors, including increased levels of sedentary behavior and easy access to high-energy foods, the prevalence of T2D has risen sharply in recent decades, presently affecting over 300 million individuals worldwide [3]. The predicted trajectory of diabetes is grim, with current estimates of the number of people affected with the disease exceeding 520 million within fifteen years [4]. At this time, T2D is the eighth leading cause of death worldwide and accounts for approximately 2.7% of all deaths [5]. For most industrialized countries, T2D represents a major public health concern.

The etiology of T2D remains incompletely understood, although insulin is recognized as the key mediator of disease development [1, 2]. The pathogenesis of the disease is complex and multifactorial, and genetic predisposition, environmental exposures, and lifestyle factors mediate susceptibility to T2D [6]. However, while obesity, increased
levels of sedentary behavior, and aging are known to contribute to an elevated risk of developing T2D, there is also a substantial proportion of people who do not develop the disease in the face of these exposures. In addition, while genome-wide association studies have identified a number of polymorphisms, together they account only for a small proportion of the inter-individual variation in disease susceptibility [7-10]. Notably, nearly 90% of the variants identified to date map to non-protein coding regions, a finding which challenges our understanding of the functional impact of such genetic factors [11-13]. Despite intense research efforts to identify specific biological targets and signaling pathways relative to these factors, the molecular mechanisms by which environmental influences affect the pathogenesis of T2D in susceptible individuals remain largely unknown. Growing evidence implicates members of a relatively new class of nucleic acids, non-coding RNAs (ncRNAs), in the etiology of T2D and, given the expression patterns and function of these molecules, as discussed below, ncRNAs may also represent potential mediators of environmental influences on pathological mechanisms underpinning the disease [14].

Approximately 90% of the human genome is transcribed [11]. In contrast to the central dogma underlying the transmission of genetic information from DNA to RNA to protein, only a small percentage of transcripts in the human transcriptome give rise to proteins, Indeed, most of the human transcriptome is transcribed as non-coding RNA (ncRNA), that is, RNA that does not encode protein [11, 13]. ncRNA can be broadly classified into two classes: infrastructural and regulatory. Infrastructural ncRNA molecules are involved in mRNA translation (ribosomal RNA and transfer RNA), as well as splicing and rRNA modification (small nuclear RNA and small nucleolar RNA, respectively). In contrast, regulatory ncRNAs mainly regulate gene expression and consist of a repertoire of different species including microRNAs (miRNAs), Piwi-interacting RNAs (pi-RNAs), small interfering RNAs (siRNAs), promoter-associated RNAs (paRNAs), enhancer RNAs (eRNAs), ajid non-coding RNAs (lncRNAs) [15, 16].

Regulatory ncRNAs are commonly characterized by transcript size, but there are additional differences in both biological function and molecular/cellular effects that serve to distinguish among them. The best-characterized members of the small regulatory ncRNAs are miRNAs, which are endogenous, single-stranded RNAs (21-25 nucleotides in length) that regulate gene expression by
blocking translation or promoting cleavage of specific target mRNAs, or less frequently, by targeting the promoter region [17]. miRNAs exert effects through specific base pair recognition mechanisms to modulate expression of target genes [18, 19] and approximately 20-30% of all human genes are transcriptionally regulated by miRNAs via targeting sequences in the 3' untranslated region (3' UTR) [20, 21]. Aberrant regulation of miRNAs has been shown to play a role in the regulation of gene expression, genomic imprinting, maintenance of pluripotency, nuclear organization and compartmentalization, and alternative splicing [34, 37-39]. Like miRNAs, IncRNAs have been found to be dysregulated in human diseases, although the role these molecules play in the disease process is not understood nearly as well [40, 41]. However, although far less is known about the impact of IncRNAs in the development of T2D, there is growing evidence that these molecules also contribute to β-cell dysfunction in response to hyperglycemia.

The role of ncRNAs in the pathogenesis of T2D has only recently become recognized, but there is already convincing support for their involvement in many of the pathophysiological mechanisms underlying the disease. The goal of this review article is to summarize the current state of knowledge of miRNAs that have been implicated in both...
Noncoding RNAs and Type 2 Diabetes

The Review of DIABETIC STUDIES
Vol. 12 ⋅ No. 3-4 ⋅ 2015/2016

Genetics of Type 2 Diabetes 263
Special Edition

www.The-RDS.org

β-cell function and regulation of insulin sensitivity or insulin action. This review also addresses the role of genetic variation in either miRNAs or miRNA binding sites within target mRNAs in the pathogenesis of T2D. Finally, an overview of the studies conducted to date is provided, with a focus on lncRNAs that are dysregulated in human pancreatic islets.

2. The role of miRNAs in T2D pathogenesis

2.1 miRNAs involved in the regulation of pancreatic β-cell function

Pancreatic β-cells are specialized endocrine cells that synthesize and secrete insulin in response to glucose stimulation. When β-cell functioning is compromised, typically through autoimmune destruction, chronic metabolic derangement, or exposure to environmental factors, insulin secretion decreases, glucose homeostasis becomes impaired, and diabetes mellitus may eventually develop. In addition to genetic and environmental influences, miRNAs have been shown to regulate biological processes in the β-cell, including β-cell differentiation and proliferation, as well as insulin biosynthesis and secretion. These miRNAs and their mechanisms of action have been extensively reviewed elsewhere [28, 42-44]. In this review, we focus mostly on recent findings in the field of miRNAs involved in the regulation of β-cell function relative to insulin resistance and T2D (Table 1).

To investigate the overall importance of miRNAs in β-cells, Kalis et al. generated mice with a β-cell-specific disruption of Dicer1 [24], an endoribonuclease that plays a critical role in the processing and generation of miRNAs [45]. Dicer1-depleted mice exhibited reduced insulin gene expression and impaired insulin secretion, both of which preceded the development of progressive hyperglycemia and diabetes. These animals also showed altered islet cell morphology, reduced β-cell mass, and differential pancreatic islet morphology, although fetal and neonatal β-cell development and insulin secretory function were normal [24, 26]. Thus, despite normal β-cell development, disruption of the miRNA network effectively resulted in defective insulin secretion, hyperglycemia, and diabetes, implying a significant function for miRNAs in this cell type. In another study, Yan and colleagues observed that the tissue-specific diurnal expression of Dicer1 was attenuated by diabetes [46]. Loss of Dicer1 rhythmicity corresponded with altered circadian expression patterns of specific miRNAs, including miR-146a and miR-125a-5p, indicating that diabetes produces effects on Dicer-controlled miRNAs. These results also suggest that restoring Dicer1 activity may potentially reverse some of the deleterious consequences of diabetes on specific miRNAs. Additional studies are necessary to address this intriguing possibility.

The role of miR-375 in pancreatic β-cell development and function has been well established. In islets, overexpression of miR-375 inhibits glucose-induced insulin secretion, while suppression of its function results in increased levels of insulin secretion [47]. One of the first validated targets of miR-375 was myotrophin (MTPN), and its inhibition produced effects on glucose-stimulated insulin secretion comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated insulin secretion and release comparable to miR-375. Levels of PDK1 (3′-phosphoinositide-dependent protein kinase-1), another target of miR-375, increased in response to glucose-stimulated
and hepatic glucose output, and higher levels of fasting and fed glucagon [49]. In these animals, impaired β-cell proliferation corresponded with decreased β-cell mass. In db/db mice, a model of increased β-cell mass and obesity-related diabetes, islet miR-375 expression was increased [49], while in fed diabetic Goto-Kakizaki (GK) rats, a model for non-obese insulin resistance and T2D, islet miR-375 expression was reduced [48]. Deletion of miR-375 in db/db mice (375/ob) led to a severe reduction in the proliferative capacity of the endocrine pancreas, resulting in diabetes [49]. Interestingly, targeted knockdown of miR-375 in zebrafish corresponded with aberrant migration of pancreatic islet cells and malformation of the endocrine pancreas [50]. In summary, the findings from animal studies provide compelling evidence that miR-375 plays an important role in β-cell function, and indicate that dysregulation of this miRNA may contribute significantly to the development of diabetes.

In humans, several studies have shown that miR-375 is upregulated in the pancreas or plasma of patients with T2D compared to non-diabetic individuals [48-50, 53], while others found no evidence for differential expression [54] or observed decreased expression levels in individuals with impaired glucose tolerance [55]. Altered miR-375 expression has been correlated with changes in methylation status of its promoter [51, 52, 55]. Increased pancreatic miR-375 expression was associated with islet amyloid deposition, decreased β-cell mass, and reduced islet mitochondrial density, but the mechanism by which this miRNA contributes to these manifestations is not yet known [53]. In miRNA profiling analyses of primary human islets and enriched β-cell preparations, discussed in detail below, high expression of miR-375 was observed, predominantly in β-cells [51]. Together, the results reported thus far are consistent with a role for miR-375 in glucose homeostasis and pancreatic β-cell expansion in response to the increasing insulin demands associated with insulin resistance and T2D in humans [56].

Latrelle et al. recently performed a comprehensive assessment of miR-7, a highly conserved, prototypical neuroendocrine miRNA [57]. Levels of miR-7 were 15-fold higher in pancreatic islets compared to adenral glands, and of the miR-7 precursors, miR-7a2 was the most abundantly expressed in islets. To investigate the role of miR-7a in pancreatic β-cells, the researchers generated Mir7a2 conditional knockout mice and found that miR-7a2 deletion in β-cells improved glucose tolerance by increasing insulin secretion. miR-7a2 was found to regulate β-cell function by directly regulating genes such as Snca, Cspa, Cplx1, Pkb1, Basp1, Pfn2, Wipf2, and Zdhhc that control late stages of insulin granule fusion with the plasma membrane and ternary SNARe complex activity. Levels of miR-7a were significantly decreased in compensating islets of high fat diet-fed and ob/ob mice, as well as normoglycemic and compensating BKS db/db mice, but were increased in decompensating BKS db/db islets. To demonstrate the pathological significance of increased miR-7a lev-

Table 1. miRNAs implicated in T2D pathogenesis

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-375</td>
<td>Reduces glucose-induced insulin secretion, decreases β-cell mass, reduces proliferative capacity of endocrine pancreas</td>
<td>[48-50, 53]</td>
</tr>
<tr>
<td>miR-7</td>
<td>Regulates insulin secretion</td>
<td>[57]</td>
</tr>
<tr>
<td>miR-124a</td>
<td>Regulates insulin secretion, regulates Foxa2 expression, participates in regulation of IAPP expression</td>
<td>[58]</td>
</tr>
<tr>
<td>miR-184</td>
<td>Reduces glucose-induced insulin secretion</td>
<td>[61]</td>
</tr>
<tr>
<td>miR-29a/b</td>
<td>Regulates MCT1 expression in β-cells, decreases insulin-stimulated glucose uptake in adipocytes</td>
<td>[63]</td>
</tr>
<tr>
<td>miR-24</td>
<td>Increases β-cell proliferation, reduces insulin secretion</td>
<td>[64]</td>
</tr>
<tr>
<td>miR-187</td>
<td>Regulates glucose-induced insulin secretion</td>
<td>[65]</td>
</tr>
<tr>
<td>miR-9</td>
<td>Reduces glucose-induced insulin secretion, regulates OneCut2 and sirt1 expression in β-cells</td>
<td>[67, 68]</td>
</tr>
<tr>
<td>Let-7/lin28a</td>
<td>Regulates glucose-induced insulin secretion, affects insulin signaling in muscle, affects glucose tolerance, increases glucose uptake</td>
<td>[69, 92]</td>
</tr>
<tr>
<td>miR-320</td>
<td>Regulates insulin sensitivity, affects insulin-stimulated glucose uptake</td>
<td>[91]</td>
</tr>
<tr>
<td>miR-143</td>
<td>Promotes adipogenesis and lipid metabolism, downregulates insulin-stimulated AKT activation, affects glucose metabolism</td>
<td>[67, 68, 98-100, 122]</td>
</tr>
<tr>
<td>miR-103/107</td>
<td>Regulates gluconeogenesis and insulin signaling</td>
<td>[98]</td>
</tr>
</tbody>
</table>
els in pancreatic islets of diabetic BKS db/db mice, transgenic mice overexpressing miR-7a in ß-cells were generated. These animals developed hyperglycemia, reduced plasma insulin levels, and impaired glucose-stimulated insulin secretion, but showed no changes in ß-cell proliferation or apoptosis. Together, these findings established miR-7 as the first negative regulator of insulin secretion in ß-cells through a network regulating insulin granule exocytosis in pancreatic ß-cells.

In addition to miR-375 and miR-7, miR-124a and miR-184 have been shown to affect ß-cell function. In pancreatic islets from T2D donors, miR-124a was expressed at much higher levels compared to normal islets [54]. Overexpression of miR-124a in MIN6 cells resulted in impaired glucose-stimulated insulin secretion and silencing of this miRNA correlated with increased expression of predicted target genes of relevance to ß-cell function, including Mtpn, Foxa2, Flot2, Akt3, Sirt1, and NeuroD1. Preliminary functional analyses showed that miR-124a bound to the 3'UTRs of both Mtpn and Foxa2. Likewise, in MIN6 cells overexpressing or underexpressing miR-124a, levels of Foxa2 were reduced or elevated, respectively [58]. A correlation between Foxa2 protein levels and decreased expression of pdx-1, Kir6.2, Sur-1, and Preproinsulin, all of which are involved with ß-cell function, insulin secretion, and glucose metabolism, revealed a potential set of pathways by which miR-124a might contribute to diabetes pathogenesis through regulation of its target mRNA [58]. In a different signaling cascade, overexpression of miR-124a was found to correspond with decreased Foxa2 expression and reduced binding to the islet amyloid polypeptide (IAPP) promoter, resulting in lower levels of IAPP mRNA and protein expression [59]. In addition, miR-124a overexpression also inhibited induction of IAPP expression by thioredoxin-interacting protein (TXNIP), which is known to play a crucial role in glucotoxicity. Thus, the miR-124a/TXNIP/Foxa2/ IAPP signaling cascade may link the TXNIP and IAPP pathways in the ß-cell.

The expression of miR-184, which is highly enriched in pancreatic islets, has been negatively correlated with insulin secretion [60] and significant inhibition of glucose-stimulated insulin secretion in MIN6 cells [61] via mechanisms involving suppression of its target, Slc25a22. miR-184 showed expression changes in two different mouse models of obesity-induced diabetes prior to the onset of disease, but was also found to have positive effects on ß-cell activity and mass [62]. Another study found that miR-29a/b directly binds the 3'UTR of the membrane monocarboxylate transporter (MCT1) in both human and mouse ß-cells [63]. The two miRNAs were both found to target endogenous Mct1, leading to decreased protein expression. Inhibition of miR-29a in primary mouse islets corresponded to increased Mct1 mRNA levels, demonstrating that miR-29 isoforms contribute to silencing of MCT1 in ß-cells, which may affect insulin release.

Other miRNAs with potential effects in pancreatic islets have been identified. For example, overexpression of miR-24 was correlated with ß-cell proliferation and reduced insulin secretion in islets from db/db mice fed a high-fat diet [64]. Targets of miR-24 included Hnf1a and neurod1, both of which are known to cause maturity-onset diabetes of the young (MODY). Inhibition of either Hnf1a or neurod1 mimicked the effects of miR-24 overexpression, suggesting that miR-24 and specific MODY genes represent a novel pathway that may contribute to the pathogenesis of T2D, possibly through mechanisms involving over-nutrition. Expression of another miRNA, miR-187, was found to be approximately seven-fold more abundant in pancreatic islets from T2D patients compared to healthy controls, and was inversely correlated with glucose-induced insulin secretion in normoglycemic individuals [65]. Overexpression of this miRNA also decreased glucose-induced insulin secretion in primary cultures of rat islets and INS-1 cells, without affecting either insulin content or apoptotic index [65]. Homeodomain interacting protein kinase 3 (HIPK3), which regulates insulin secretion and glucose tolerance [66], was identified and validated as a direct miR-187 target, and levels of HIPK3 were reduced in islets from patients with T2D, suggesting that miR-187 may exert effects on glucose-stimulated insulin secretion through mechanisms involving MODY [65]. Evidence for another miRNA, miR-9, demonstrated an effect on glucose-induced insulin secretion through the inhibition of OneCut2 expression in ß-cells [67]. Elevated miR-9 also diminished sirt1 expression in ß-cells [68]. Additional functional studies are expected to further clarify the roles of all of these miRNA/mRNA relationships in the pathogenesis of T2D.

In addition to single miRNAs, networks of miRNA may also contribute to glucose homeostasis. For example, transgenic mice with global and pancreas-specific Cre-inducible activation of Let-7a, Let-7d, and Let-7f expression exhibited reduced glucose-stimulated insulin secretion, resulting in impaired glucose tolerance [69]. In contrast, global knockdown of the Let-7 family members
prevented obesity-induced glucose intolerance and restored insulin signaling in muscle and liver. Together, the results demonstrate that Let-7 influences different aspects of glucose metabolism in multiple tissues, and that inhibition of Let-7 may improve pancreatic \( \beta \)-cell function. However, the precise role that this family of miRNAs plays in the pathogenesis of the disease remains to be determined.

2.2 miRNA profiling of pancreatic islets and \( \beta \)-cells

A number of studies have recently applied miRNA profiling approaches in pancreatic islets or \( \beta \)-cells from diabetic and non-diabetic donors to gain new insight into the molecular mechanisms underlying T2D. A comprehensive investigation by van de Bunt and colleagues [31] utilized next generation sequencing to profile the miRNA fraction in primary human islets and preparations of \( \beta \)-cells enriched by fluorescence-activated cell sorting to purity levels \( \geq 90\% \). The authors identified 366 and 346 miRNAs that were expressed in islets and enriched \( \beta \)-cells, respectively, including a total of 384 unique miRNAs, of which 328 were shared between islets and \( \beta \)-cells. The miRNA expression profiles in islets and \( \beta \)-cells were strongly correlated \( (r^2 = 0.78) \), although miR-375 was present at significantly higher levels in \( \beta \)-cells compared to islets \( (42\% \text{ vs. } 27\%) \). In contrast, levels of miR-143-3p were much lower in \( \beta \)-cells \( (2\% \text{ vs. } 16\%) \). Some of the most highly expressed miRNAs identified in islets were those that had been previously identified in other studies, including miR-375, miR-7-5p, miR-148a-3p, miR-26a-5p, and miR-127-3p [31], while others, such as miR-27b-3p and miR-192-5p, represented novel findings. In comparisons with publically available miRNA expression data for over fifteen different human tissues, the authors determined that 40 of the 366 miRNAs identified were islet-specific. Several of the ten most tissue-specific miRNAs have been previously implicated in islet function (miR-184, miR-375, miR-182-5p, and miR-127-5p), while others (miR-409-5p, miR-1468, miR-183-5p, miR-136-3p, miR-370, and miR-153) represent potentially novel players in the maintenance of islet identity.

Klein et al. also assessed miRNA profiles in enriched preparations of pancreatic \( \alpha \)- and \( \beta \)-cells from six human pancreases using a microarray approach [70]. The majority of miRNAs were preferentially expressed in \( \beta \)-cells: out of the 141 miRNAs identified in the analyses, only seven were expressed in \( \alpha \)-cells. Several of the identified \( \beta \)-cell-specific miRNAs have been previously associated with the regulation of insulin expression and content and/or overlapped with the findings from van de Bunt et al. including miR-204, miR-127-3p, miR-184, miR-148, miR-29, miR-375, and miR-7 [31]. The transcription factor, cMaf, which is expressed exclusively in \( \alpha \)-cells where it regulates expression of the glucagon gene, was identified as a target for several \( \beta \)-cell-specific miRNAs, including miR-125b, miR-182, and miR-200c, which showed 27.3-, 9.7-, and 3.3-fold higher expression in \( \beta \)-cells compared to \( \alpha \)-cells [70]. Inhibition of these three miRNAs in MIN6 cells resulted in increased cMaf expression, while their overexpression in \( \alpha \)TC6 cells corresponded with decreased cMaf expression.

The work of van de Bunt et al. [31] and Klein et al. [70] was performed using islets from donors without a known T2D diagnosis. In addition to these investigations, a small number of profiling studies have been performed using islets from diabetic donors. For example, a recent microarray analysis to profile miRNAs in pancreatic islets of prediabetic and diabetic db/\( db \) mice and mice fed a high-fat diet identified two distinct categories of differentially expressed molecules [62]. miR-132, miR-184, and miR-338-3p exhibited expression changes in islets well before the onset of diabetes, while miR-34a, miR-146a, miR-199a-3p, miR-203, miR-210, and miR-383 showed differences mostly in diabetic mice. Expression changes in prediabetic animals exerted positive effects on \( \beta \)-cell activity and mass, and those in diabetic mice increased \( \beta \)-cell apoptosis. These findings suggest that obesity and insulin resistance produce changes in miRNAs, with initially sustained \( \beta \)-cell function, but \( \beta \)-cell loss and development of T2D after further deregulation in additional miRNAs [62]. These results also indicated that the maintenance of glucose homeostasis, or in contrast, the development of glucose intolerance, might be mediated by alterations in expression patterns of specific miRNAs.

In a global profiling assessment of 384 miRNAs in pancreatic islets from non-obese T2D GK and non-diabetic Wistar rats, Esquerra et al. identified 30 differentially expressed miRNAs, most of which were upregulated in diabetic islets [71]. Glucose-induced insulin secretion experiments using isolated islets from GK and control animals revealed significant differences in the magnitude and direction of miRNA expression, suggesting differences in short- and long-term glucose dependence. In GK rats, expression of miR-130a, miR-132, miR-212, and miR-335 was regulated by hyperglycemia and
Noncoding RNAs and Type 2 Diabetes

The authors hypothesized that the insulin secretion defects in the GK rat may be due, in part, to upregulation of miRNAs that regulate key proteins involved in insulin exocytosis from β-cells. In support of these findings, glucose regulation of miR-132 and miR-212 were also reported in MIN6 cells [72], and these two miRNAs were upregulated in pancreatic islets in obese mice [73], suggesting a common pathway for these ncRNAs in disease pathogenesis for both diabetic GK rats and obese mice models.

In humans, Bolmeson et al. compared global miRNA expression patterns in islets from nine healthy donors and six glucose intolerant individuals using a bead-based technology [60]. A total of 319 miRNAs were measured, and of these, miR-375, miR-127-3p, miR-184, and miR-493 showed enrichment in pancreatic islets compared to liver and skeletal muscle. In islets from glucose intolerant donors, levels of miR-21, miR-375, and miR-184, and miR-127-3p were increased compared to normal islets and expression of miR-375, miR-122, and miR-184, and miR-127-3p correlated positively with insulin gene expression, indicating that some of these miRNAs may be exerting effects on glucose homeostasis through insulin synthesis. A similar study assessed miRNA content using TaqMan arrays in islets from 11 T2D donors and nine controls [65]. Of the 667 miRNA assays on the array, 255 amplified in all samples. Of these, only miR-187 and miR-345 showed statistically significant differential expression between islets from diabetic donors and unaffected controls. In an independent sample of islets from ten individuals with T2D and ten without the disease, the authors continued to observe significantly higher levels of miR-187, but not miR-345. Levels of miR-187 were also inversely correlated with glucose-stimulated insulin secretion in a sample of 35 normoglycemic donors [65]. In earlier studies of the islet miRNome conducted in donors without known T2D [31, 70], miR-187 levels were low or undetectable, suggesting that expression of this miRNA corresponds with the deteriorating condition of the β-cell during the progressive development of T2D.

**Table 2. Major findings from miRNA profiling studies**

<table>
<thead>
<tr>
<th>Model</th>
<th>Source</th>
<th>Approach</th>
<th>Major miRNAs identified</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>GK rats</td>
<td>Islets</td>
<td>Microarray</td>
<td>miR-130a, miR-132, miR-212, miR-335</td>
<td>[71]</td>
</tr>
<tr>
<td>Humans (nondiabetic)</td>
<td>Islets</td>
<td>Sequencing</td>
<td>miR-7-5p, miR-26a-5p, miR-27b-3p, miR-127-3p, miR-148a-3p, miR-192-5p, miR-375</td>
<td>[31]</td>
</tr>
<tr>
<td>Humans (nondiabetic)</td>
<td>α- and β-cells</td>
<td>Microarray</td>
<td>miR-7, miR-29, miR-127-3p, miR-148, miR-184, miR-204, miR-375</td>
<td>[70]</td>
</tr>
<tr>
<td>db/db mice</td>
<td>Islets</td>
<td>Microarray</td>
<td>miR-34a, miR-132, miR-146a, miR-184, miR-199a-3p, miR-203, miR-210, miR-383</td>
<td>[62]</td>
</tr>
<tr>
<td>Glucose intolerant vs. normoglycemic humans</td>
<td>Islets</td>
<td>Bead-based hybridization</td>
<td>miR-21, miR-127-3p, miR-375</td>
<td>[60]</td>
</tr>
<tr>
<td>T2D vs. normoglycemic humans</td>
<td>Islets</td>
<td>Microarray</td>
<td>miR-187</td>
<td>[65]</td>
</tr>
<tr>
<td>T2D vs. normoglycemic humans</td>
<td>Islets</td>
<td>Sequencing</td>
<td>miR-7-1-3p, miR-7-3-5p, miR-23c, miR-30a-5p, miR-187-3p, miR-216a-5p, miR-369-3p, miR-487a-3p, miR-495-3p, miR-539-3p, miR-54a-5p, miR-589-5p, miR-656-3p, miR-4716-3p</td>
<td>[74]</td>
</tr>
<tr>
<td>Normoglycemic humans</td>
<td>Muscle</td>
<td>Microarray</td>
<td>miR-1, miR-133a, miR-306</td>
<td>[93]</td>
</tr>
<tr>
<td>T2D humans</td>
<td>Muscle</td>
<td>Microarray</td>
<td>miR-15a, miR-15b, miR-98, miR-99a, miR-100a, miR-106b, miR-133a, miR-133b, miR-143, miR-152, miR-165, miR-190</td>
<td>[96]</td>
</tr>
<tr>
<td>GK rats</td>
<td>Fat, liver, muscle</td>
<td>Microarray</td>
<td>miR-10b, miR-27a, miR-103, miR-195, miR-222</td>
<td>[97]</td>
</tr>
</tbody>
</table>

**Legend:** 1 Non-obese diabetic. 2 Prediabetic and diabetic. 3 Before and after 3-hr euglycemic-hyperinsulinemic clamp. 4 Skeletal muscle. 5 Hyperglycemic vs. intermediate glycemic (Wistar Kyoto) and normoglycemic (Brown Norway) rats.
several were derived from the maternally expressed, imprinted DLK1-MEG3 locus on 14q32. As seen in earlier studies [70, 75], expression levels of the 14q32 miRNAs and the long non-coding MEG3 RNA were ~16-20-fold higher in β-cells compared to γ-cells. Potential targets of the 14q32 miRNAs included islet amyloid polypeptide (IAPP) and p53-induced nuclear protein 1 (TP53INP1), both of which increase β-cell apoptosis when overexpressed in islets. A direct targeting relationship was observed between miR-376a and miR-432 and the IAPP 3'UTR. TP53INP1 transcript levels were increased in islets from donors with T2D compared to non-diabetic individuals and miR-495 was found to downregulate TP53INP1 expression.

Unlike investigations of circulating miRNAs as potential markers for T2D where there is minimal overlap among reported findings [76-85], miRNA profiling studies in islets and β-cells have shown strongly consistent results (Table 2). At this time, however, little is known of the potential targets of these miRNAs and the mechanisms by which they affect disease development in susceptible individuals. Additional studies aimed at delineating specific miRNA/mRNA networks and consequent effects on β-cell function are expected to further enhance our understanding of the complex pathogenesis of T2D.

### 2.3 miRNA dysregulation in insulin-sensitive peripheral tissues

Glucose homeostasis is maintained by a balance between the amount of insulin released by pancreatic β-cells and the action of the hormone at insulin-sensitive target tissues. During the development of insulin resistance, target tissues become less sensitive to insulin, which leads to progressive hyperglycemia. Age, obesity, diet, and hypertension are known to affect insulin sensitivity of target tissues, but the precise mechanisms by which insulin resistance develops remain an area of active focus. Just as miRNAs contribute to dysregulation of β-cell function, there is now compelling evidence supporting a role for these ncRNAs in the development of insulin resistance (Table 1).

For example, expression of miR-29a/b/c was elevated in muscle, fat, and/or liver of diabetic rats [86], fa/fa rats, and high-fat diet-fed mice [87]. Overexpression of miR-29a/b/c in 3T3-L1 adipocytes decreased insulin-stimulated glucose uptake by inhibiting P85alpha and AKT activation [86, 88], and led to insulin resistance through mechanisms not involving AKT as the direct target of the miRNA [86]. Overexpression of miR-29a in HepG2 cells prevented insulin-mediated inhibition of the phosphoenolpyruvate carboxykinase gene (PEPCK) by repressing the p85alpha gene, the upstream intermediate of AKT [89]. As noted above, miR-29a/b/c also plays a known role in insulin signaling through mechanisms involving MCT1 [63, 90].

Another miRNA, miR-320, has also been shown to play a role in the regulation of insulin sensitivity. Expression of miR-320 in insulin resistant 3T3-L1 adipocytes was 50-fold higher compared to normal adipocytes [91]. Inhibition of this miRNA in 3T3-L1 cells led to improved insulin sensitivity. The p85 subunit of phosphatidylinositol 3-kinase (PI3-K) was identified as a potential miRNA target, and knockdown of miR-320 not only corresponded with increased expression of p85, but also with elevated expression of glucose transporter type 4 (GLUT-4), improved insulin-stimulated glucose uptake, and elevated phosphorylation of AKT [91]. Notably, these findings were observed only in insulin-resistant 3T3-L1 cells and not in normal adipocytes, suggesting that the dysregulation of insulin action leads to alterations in the miR-320/p85 pathway that further exacerbate the condition of insulin resistance.

Transgenic mice overexpressing lin28a displayed improved glucose tolerance and were resistant to high fat diet-induced diabetes, while animals with muscle-specific lin28a deletion and inducible let-7 exhibited glucose intolerance [92]. Functional analyses demonstrated that lin28a, which blocks let-7 miRNAs, increases glucose uptake through insulin-PI3K-mTOR signaling by depressing direct let-7 targets in this pathway, including insulin-like growth factor 1 (IGF1R), insulin receptor (INSR), insulin receptor substrate 2 (IRS2), phosphoinositide-3-kinase interacting protein 1 (PIK3IP1), v-akt murine thymoma viral oncogene homolog 2 (AKT2), tuberous sclerosis 1 (TSC1) and RPTOR independent companion of mTOR, complex 2 (RICTOR). Inhibition of mTOR demonstrated a role for Lin28a glucose tolerance and insulin sensitivity in an mTOR-dependent response [92]. These results provide strong evidence that the Lin28a/let-7 pathway may be a prime factor in the regulation of glucose metabolism.

Granjon et al. compared miRNA expression profiles in skeletal muscle biopsies from healthy individuals before and after a 3-hour euglycemic-hyperinsulinemic clamp, and observed downregulation of three miRNAs by insulin: miR-1, miR-133a, and miR-306 [93]. miR-1 and miR-133a both play roles in myoblast biology, but while miR-1 in-
Potential combinatorial nature of miRNA action approaches, the authors determined that the potentially catalytic role of miRNA action in disease. Using bioinformatics, miRNAs showed differential expression patterns in the disease process. Of these, ~15% of the dysregulated miRNAs in skeletal muscle from individuals with T2D [96]. Of these, only five had expression levels that differed significantly among individuals with normal glucose tolerance, impaired glucose tolerance, and T2D, and an association between higher fasting glucose levels and lower miR-133a expression was also observed in these patients [96].

A separate study by Gallagher and colleagues reported differential expression of 62 out of 171 miRNAs in skeletal muscle from individuals with T2D [96]. Of these, ~15% of the dysregulated miRNAs showed differential expression patterns early in the disease process. Using bioinformatics approaches, the authors determined that the potential combinatorial nature of miRNA action in vivo underlies significant changes in target protein levels, which then contributes to the development of insulin resistance and T2D. In an analysis of 283 miRNAs in adipose tissue, skeletal muscle, and liver from hyperglycemic (GK), intermediate glycemic (Wistar Kyoto), and normoglycemic (Brown Norway) rats, 49 differentially expressed miRNAs were identified across the three tissues [97]. Of these, only five had expression levels that correlated with degree of glycemia, including miR-222 and miR-27a, which were upregulated in adipose tissue, miR-195 and miR-103, which were upregulated in liver, and miR-10b, which was downregulated in muscle. Expression patterns for miR-222, miR-27a, and miR-29a were validated in 3T3-L1 adipocytes cultured under hyperglycemic conditions, suggesting that altered miRNA expression may occur early in the pathogenesis of T2D.

An examination of liver-specific miRNA expression in db/db and diet-induced obese mice identified miR-103/miR-107 as two of the most significantly upregulated miRNAs [98], validating findings from hyperglycemic GK rats [97]. Of note, the sequences of mature miR-103 and miR-107 differ only at one nucleotide, and are thus nearly indistinguishable from each other. Expression of miR-103 and miR-107 was also increased in liver biopsies from individuals with non-alcoholic fatty liver disease, which often accompanies obesity and T2D, and levels of these miRNAs were positively correlated with homeostatic model assessment (HOMA) index [98]. Overexpression of miR-107 in the liver resulted in excess glucose output through a mechanism involving increased gluconeogenesis. Knockdown of miR-103 and miR-107 corresponded with improved insulin signaling in liver and adipose tissue, although targeted silencing of these miRNAs in the liver did not ameliorate the metabolic abnormalities observed in these animals. The investigators identified cavedin-1 as a direct target of miR-103/miR-107. Inhibition of miR-103/miR-107 in adipocytes led to upregulation of cavedin-1 expression, which was accompanied by insulin receptor stabilization, improved insulin signaling, decreased adipocyte size, and enhanced insulin-stimulated glucose uptake. Elucidation of the mechanism by which the miR-103/107-caveolin interaction regulates insulin signaling may have important implications for the development of these miRNAs as potential targets for T2D treatment [98].

A sequencing analysis of small RNA molecules extracted from the livers of mice with either free or restricted access to food, as well as fasted/refed animals, found that out of 32 confirmed miRNAs, only one, miR-143, varied with feeding conditions [99]. In db/db mice and mice fed a high-fat diet, hepatic miR-143 expression was upregulated. Another miRNA, miR-145, which is located in the same gene cluster as miR-143, was also upregulated in livers of these two animal models. Inhibition of miR-143 expression protected mice from diet-induced insulin resistance and AKT activation, while miRNA overexpression disrupted insulin-stimulated AKT activation and led to impaired glucose metabolism [99]. A potential miR-143 target, oxysterol-binding protein-related protein 8 (ORP8), was identified, and decreased hepatic expression of this target led to impaired insulin-induced AKT activation. A similar sequence analysis of hepatic ncRNA in ob/ob and control mice revealed 37 differentially expressed miRNAs [100], with miR-122 showing the greatest expression changes between the two groups, followed by miR-24, miR-195a, miR-106b, miR-15b, miR-185, miR-214, miR-378, and let-7c (upregulated), and miR-224, miR-126, miR-7a, miR-128, miR-455, miR-452, miR-135b, miR-145, miR-18a, and miR-196a (downregulated).
2.4 Genetic variation, miRNAs, and susceptibility to T2D

Polymorphisms located in regulatory regions of miRNA genes can affect miRNA processing and expression, while those in the miRNA seed region can potentially attenuate or abolish miRNA binding to target mRNAs or create new interactions with non-target mRNAs [101, 102]. Likewise, variants in miRNA target sites may disrupt gene expression, leading to altered risk of developing disease [103-105]. Given the importance of miRNAs in the regulation of homeostatic processes, it is not surprising that miRNA-related polymorphisms have been associated with a diverse array of diseases [106-108]. Over the past two years, growing evidence is beginning to support a role for genetic variation in miRNAs and miRNA target sites, yielding an additional level of complexity associated with the development of T2D.

In their analysis of human islet and β-cell miRNAs discussed above, van de Bunt and colleagues [31] identified over 6000 variants in miRNA transcripts and predicted miRNA target sites overlapping genome-wide levels of statistical significance (p = 1.45 x 10^-8). Of these, rs3802177, located in the 3'UTR of SLC30A8, was the only variant that reached genome-wide levels of significance (p = 1.45 x 10^-6). The sequence harboring this variant corresponded to predicted target sites for several miRNAs including miR-363-3p, miR-25-3p, miR-32-5p, miR-92a-3p, miR-33a-5p, and miR-33b-5p. The authors also observed that predicted mRNA targets of islet miRNAs were enriched for T2D association signals and identified overlap between variants in miRNA sequence and/or predicted miRNA targets and six loci (AP3S2, KCNK16, NOTCH2, SLC30A8, VPS26A, and WFS1) showing genome-wide evidence for association with T2D [31].

In a study of 1017 T2D cases and 1059 controls, Zhao et al. analyzed ten polymorphisms located in diabetes-related miRNA-target gene regulation data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium [109]. Of these, rs3802177, located in the 3'UTR of SLC30A8, was the only variant that reached genome-wide levels of statistical significance (p = 1.45 x 10^-6). The sequence harboring this variant corresponded to predicted target sites for several miRNAs including miR-363-3p, miR-25-3p, miR-32-5p, miR-92a-3p, miR-33a-5p, and miR-33b-5p. The authors also observed that predicted mRNA targets of islet miRNAs were enriched for T2D association signals and identified overlap between variants in miRNA sequence and/or predicted miRNA targets and six loci (AP3S2, KCNK16, NOTCH2, SLC30A8, VPS26A, and WFS1) showing genome-wide evidence for association with T2D [31].

In a study of 1017 T2D cases and 1059 controls, Zhao et al. analyzed ten polymorphisms located in diabetes-related miRNA-target gene regulation data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium [109]. Of these, rs3802177, located in the 3'UTR of SLC30A8, was the only variant that reached genome-wide levels of statistical significance (p = 1.45 x 10^-6). The sequence harboring this variant corresponded to predicted target sites for several miRNAs including miR-363-3p, miR-25-3p, miR-32-5p, miR-92a-3p, miR-33a-5p, and miR-33b-5p. The authors also observed that predicted mRNA targets of islet miRNAs were enriched for T2D association signals and identified overlap between variants in miRNA sequence and/or predicted miRNA targets and six loci (AP3S2, KCNK16, NOTCH2, SLC30A8, VPS26A, and WFS1) showing genome-wide evidence for association with T2D [31].

In a study of 1017 T2D cases and 1059 controls, Zhao et al. analyzed ten polymorphisms located in diabetes-related miRNA-target gene regulation data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium [109]. Of these, rs3802177, located in the 3'UTR of SLC30A8, was the only variant that reached genome-wide levels of statistical significance (p = 1.45 x 10^-6). The sequence harboring this variant corresponded to predicted target sites for several miRNAs including miR-363-3p, miR-25-3p, miR-32-5p, miR-92a-3p, miR-33a-5p, and miR-33b-5p. The authors also observed that predicted mRNA targets of islet miRNAs were enriched for T2D association signals and identified overlap between variants in miRNA sequence and/or predicted miRNA targets and six loci (AP3S2, KCNK16, NOTCH2, SLC30A8, VPS26A, and WFS1) showing genome-wide evidence for association with T2D [31].

In a study of 1017 T2D cases and 1059 controls, Zhao et al. analyzed ten polymorphisms located in diabetes-related miRNA-target gene regulation data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium [109]. Of these, rs3802177, located in the 3'UTR of SLC30A8, was the only variant that reached genome-wide levels of statistical significance (p = 1.45 x 10^-6). The sequence harboring this variant corresponded to predicted target sites for several miRNAs including miR-363-3p, miR-25-3p, miR-32-5p, miR-92a-3p, miR-33a-5p, and miR-33b-5p. The authors also observed that predicted mRNA targets of islet miRNAs were enriched for T2D association signals and identified overlap between variants in miRNA sequence and/or predicted miRNA targets and six loci (AP3S2, KCNK16, NOTCH2, SLC30A8, VPS26A, and WFS1) showing genome-wide evidence for association with T2D [31].

In a study of 1017 T2D cases and 1059 controls, Zhao et al. analyzed ten polymorphisms located in diabetes-related miRNA-target gene regulation data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium [109]. Of these, rs3802177, located in the 3'UTR of SLC30A8, was the only variant that reached genome-wide levels of statistical significance (p = 1.45 x 10^-6). The sequence harboring this variant corresponded to predicted target sites for several miRNAs including miR-363-3p, miR-25-3p, miR-32-5p, miR-92a-3p, miR-33a-5p, and miR-33b-5p. The authors also observed that predicted mRNA targets of islet miRNAs were enriched for T2D association signals and identified overlap between variants in miRNA sequence and/or predicted miRNA targets and six loci (AP3S2, KCNK16, NOTCH2, SLC30A8, VPS26A, and WFS1) showing genome-wide evidence for association with T2D [31].

3. IncRNAs and T2D pathogenesis

Although far less is known of the impact of IncRNAs in the development of T2D compared to miRNAs, there is growing evidence that these molecules also contribute to β-cell dysfunction in response to hyperglycemia. A recent genome-wide search for human pancreatic islet and β-cell IncRNAs identified 1128 intergenic and antisense islet-cell IncRNAs of which 55% and 40% were islet-specific, respectively, compared to only 9.4% of RefSeq annotated genes [114]. Interestingly, this
work showed that >19% of the transcribed genome in islets mapped outside of annotated protein-coding genes. The majority of IncRNAs identified in this study were silent or expressed at low levels in pancreatic progenitors, but were active in adult islets, indicating that IncRNAs contribute in a meaningful manner to pancreatic endocrine differentiation. Similarly, during in vivo differentiation of human embryonic stem cells, six IncRNAs were expressed at very low or undetectable levels throughout all in vitro differentiation steps, and were only activated during the in vivo maturation step [114]. In a comparison of 14 islet-specific IncRNAs, KCNQ1OT1 and HI-LNC45 were significantly increased or decreased in T2D islets, respectively, and out of 55 T2D susceptibility loci, nine contained islet IncRNAs within 150 kb of the reported lead marker, six of which have been linked directly to β-cell dysfunction [109, 115-118]. Finally, as a first step toward understanding islet IncRNA function, the authors suppressed expression of a candidate IncRNA, HI-LNC25, in EndoC-βH1 cells, a human β-cell line that exhibits glucose-stimulated insulin secretion, and examined subsequent effects on 24 islet mRNAs. Levels of GLIS3, an islet transcription factor that is mutated in monogenic diabetes, were significantly reduced in response to HI-LNC25 knockdown, imparting a novel regulatory function to islet IncRNAs.

In a comprehensive DNA and RNA sequencing effort using pancreatic islets from 89 donors with different degrees of glucose tolerance, Fadista and colleagues [119] identified a number of genetic variants regulating gene expression (eQTLs) and exon use (sQTLs), including many lincRNAs. A total of 493 RefSeq islet lincRNAs were identified, 54 of which were associated with eQTLs and sQTLs. Seventeen lincRNAs were associated with Hba1c levels, including HI-LNC901 (i.e., LOC283177), which also had an eQTL (rs73036390) and whose expression was directly correlated with insulin exocytosis. HI-LNC901 was coexpressed with MAP-kinase activating death domain (MADD), synaptotagmin 11 (SYT11), and paired box 6 (PAX6), all of which have been implicated in islet function.

Other IncRNAs have been found to harbor genetic variants associated with T2D, the most notable of which is the ANRIL locus [40]. This IncRNA maps to the INK4 locus, which encodes three tumor suppressor genes including p15^INK4B. ANRIL is required for the silencing of this tumor suppressor gene [120], and it is possible that variants that disrupt the expression or function of this IncRNA may affect compensatory increases in pancreatic β-cell mass in response to increasing demands for insulin in the prediabetic state [121].

The discovery of dysregulated islet-specific IncRNAs adds a new layer of complexity to the molecular etiology of T2D. The studies reported to date, although limited in number, not only point to a role for IncRNAs in the regulation of β-cell identity and function, but also suggest that variants in islet-specific IncRNAs contribute to β-cell physiology and T2D. Functional characterization of islet-specific IncRNAs is underway [114], although a substantial amount of work is needed to understand the relative importance of these molecules in the pathogenesis of T2D. These findings, in combination with emerging results, are expected to yield new insights into the complex pathogenesis of T2D and may eventually lead to the identification of novel islet-specific therapeutic targets with limited effects in other cell types.

4. Summary

The role of ncRNAs in the pathogenesis of T2D is just beginning to emerge, but there is already ample evidence of their involvement in pathophysiological mechanisms underlying the disease. A number of miRNAs have emerged as key players in the control of β-cell function and regulation of insulin sensitivity and/or action in peripheral organs, and more will undoubtedly be identified as research in this area matures. While studies from knockout animals have demonstrated clear roles for many of these miRNAs in processes contributing to T2D pathogenesis, much less is known of the specific targets of candidate molecules and the mechanisms by which they affect disease development in susceptible individuals. Studies aimed at delineating specific miRNA/mRNA networks will enhance our understanding of the complex pathogenesis of T2D and enable exploitation of relevant miRNAs as novel targets for therapeutic interventions. The investigation of polymorphisms in miRNAs and mRNA targets, which represents an increasingly active field of research, also promises to yield new insights into the complex nature of genetic predisposition to T2D. The growing recognition of IncRNA involvement in the pathogenesis of T2D adds an exciting new layer of complexity to our understanding of both the disease and gene regulation, and the cell-specific expression patterns of these molecules may yield deeper insights into defects in specialized cellular functions.

Disclosures: The authors report no conflict of interests.
References


Dysregulated miR-155


Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. The role...
Noncoding RNAs and Type 2 Diabetes

The Review of DIABETIC STUDIES
Vol. 12 - No. 3-4 - 2015/2016

Genetics of Type 2 Diabetes 275
Special Edition


110. Locke JM, Lango Allen H, Harries LW. A rare SNP in pre-miR-34a is associated with increased levels of miR-34a in pancreatic beta cells. A d. Diabetol. 2014. 57(12):325-329.


